New oral drug aims to tackle obesity in chinese population

NCT ID NCT06023095

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests an experimental oral drug called LY3502970 in Chinese adults who have obesity or are overweight with related health problems like high blood pressure or sleep apnea. The main goal is to check the drug's safety and how the body processes it. Participants receive either LY3502970 or a placebo over several weeks, with regular blood tests and monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental oral drug called LY3502970
What this could lead to: If successful, this could lead to a new oral treatment option for weight management in people with obesity or overweight.
What could go wrong: This is an early phase 1 study with only 24 participants, so results may not apply broadly. Safety and effectiveness are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Locations

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China
Shanghai General Hospital

Shanghai, Songjiang, 201620, China
West China Hospital Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.